Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tuberculin purified protein derivative
Drug ID BADD_D02311
Description Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.
Indications and Usage Indicated as a diagnostic agent in Mantoux Test used to detect infection with *Mycobacterium tuberculosis*.
Marketing Status approved
ATC Code V04CF01
DrugBank ID DB11601
KEGG ID D06256
MeSH ID D014373
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 50090-0261; 50090-1668; 64117-409; 42023-104; 50090-1336; 49281-752
UNII I7L8FKN87J
Synonyms Tuberculin | PPD-B | PPD B | PPD-L | PPD L | Purified Protein Derivative of Tuberculin | PPD | PPD-S | PPD-CG | PPD CG | PPD-F | PPD F
Chemical Information
Molecular Formula Not Available
CAS Registry Number 92129-86-7
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Application site necrosis12.07.01.032; 08.02.01.032--Not Available
Application site ulcer08.02.01.007; 23.07.03.010; 12.07.01.007--Not Available
Discomfort08.01.08.003--Not Available
Injection site erythema12.07.03.001; 08.02.03.001; 23.03.06.015--Not Available
Injection site oedema12.07.03.024; 08.02.03.024--Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site rash12.07.03.032; 08.02.03.032; 23.03.13.010--Not Available
Injection site urticaria08.02.03.029; 23.04.02.003; 12.07.03.029; 10.01.06.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.009--Not Available
Application site scar23.03.11.010; 12.07.01.033; 08.02.01.033--Not Available
The 1th Page    1    Total 1 Pages